Pluristyx, Inc.的封面图片
Pluristyx, Inc.

Pluristyx, Inc.

生物技术

Seattle,Washington 2,953 位关注者

Providing best-in-class mRNA-reprogrammed unedited and gene-modified iPSCs for clinical development

关于我们

Pluristyx is a pioneering company at the forefront of stem cell technologies. With a mission to revolutionize the field of regenerative medicine, Pluristyx develops innovative solutions that empower breakthroughs in stem cell therapies. The company's proprietary platform, panCELLa, represents a transformative leap in stem cell research, offering enhanced freedom to operate and unparalleled potential for medical advancements at a significantly accelerated timeline. Operating from two cutting-edge North American sites, Pluristyx is dedicated to driving progress and innovation in the realm of stem cell therapies. In July of 2023 Pluristyx and panCELLa merged. Pluristyx offers a portfolio of iPSC-based products and services to provide end-to-end client support in early product development, while panCELLa offers an array of unique and effective technologies with particular strength in gene editing. As one company, Pluristyx and panCELLa offer an enlarged portfolio whose long-term focus is to become the global leader in clinical-grade, genetically modified, “off-the-shelf” iPSCs with the lowest barrier to entry for cell therapy development, providing clients with the fastest speed to clinic and the best route to commercialization.

网站
https://www.pluristyx.com
所属行业
生物技术
规模
11-50 人
总部
Seattle,Washington
类型
私人持股
创立
2018
领域
Stem cells、Cell therapy、Process development、CMC Project Management、Manufacturing、Consulting、CAR T-cells、iPSC、pluripotent stem cells、scale-up、Cryopreservation、Gene Therapy、Gene Editing、Drug Development、Regenerative Medicine、Cryopreservation、Reprogramming和GMP Banking

地点

  • 主要

    201 Elliott Ave W

    US,Washington,Seattle,98119

    获取路线

Pluristyx, Inc.员工

动态

  • 查看Pluristyx, Inc.的组织主页

    2,953 位关注者

    In collaboration with Defined Bioscience, we've published a new application note for our #PluriKit. This kit, available with our induced pluripotent stem cells, provides you with the necessary reagents to culture and generate a small working bank of #iPSCs, minimizing variability to achieve robust expansion, effective cryopreservation, and reliable post-thaw recovery. Why source from multiple vendors when you can buy what you need as a pre-packaged, validated set of reagents and protocols for consistent growth of iPSCs?

    查看Defined Bioscience的组织主页

    2,112 位关注者

    ?? New Application Note: Advancing iPSC Expansion, Cryopreservation, and Recovery ?? At Defined Bioscience, we are committed to driving innovation in pluripotent stem cell research and applications. Our latest application note, developed in collaboration with Pluristyx, Inc., showcases an optimized workflow for the expansion, cryopreservation, and recovery of clinical-grade PluriBank? iPSCs using a fully defined reagent system. App Note: Optimized Expansion, Cryopreservation, and Recovery of Clinical Grade, PluriBank? iPSCs Using a Defined Reagent System Kit ?? What’s inside? ? HiDef?-B8 Stem Cell Growth Medium – A chemically defined, serum-free solution ensuring consistent self-renewal and genetic stability. ? Ready-CEPT? Cocktail – Enhancing cell viability and reducing apoptosis during passaging and cryopreservation. ? PluriFreeze? Cryopreservation Medium – Maximizing post-thaw viability and recovery. ? Validated Protocols – Supporting reproducibility in hPSC culture while enabling flexible feeding schedules, including reduced medium exchanges without compromising quality. ?? Our findings demonstrate high cell viability, robust expansion, and stable pluripotency marker expression across different feeding regimens, providing a scalable and efficient solution for stem cell banking and downstream applications. ?? Read the full application note here: https://lnkd.in/g_quDPmH A huge thank you to our collaborators at Pluristyx for their partnership in this work! If you’re working with iPSCs and want to improve your workflow, we’d love to connect and discuss how this system can help. #StemCells #Pluripotency #iPSC #DefinedMedia #RegenerativeMedicine #Cryopreservation #Biotech #LifeSciences #DefinedBioscience #Pluristyx. Shout out to BioLamina for their great #Matrix

    • 该图片无替代文字
  • 查看Pluristyx, Inc.的组织主页

    2,953 位关注者

    Discover more about our CEO, Benjamin Fryer, his inspiration behind founding Pluristyx, and our exciting plans for 2025 in a recent interview conducted by Bullpen at #JPM2025. Our commitment to revolutionizing regenerative medicine aligns perfectly with the spirit of this event. We're proud to support the development of groundbreaking cellular therapies that have the potential to transform patient care.? #CellTherapy #Innovation #VentureCapital

    查看Bullpen的组织主页

    3,940 位关注者

    Benjamin Fryer, Founder and CEO of Pluristyx, Inc. was interviewed by James Zanewicz, JD, LLM, RTTP in the Bullpen during #JPM2025 at the Golden Gate Yacht Club in San Francisco. Thank you Tulane University School of Medicine for making these interviews happen. We hope you enjoy meeting all of our featured leaders. We encourage you to “amplify their ask” if it resonates with you. Share with your network. It’s one simple way to help them with their mission. KOL Interviews are a personal introduction to key Experts, Connectors and Dealmakers in the #Bullpen. Our #Mantra: Find Someone to Help. Repeat. Bullpen will throw some serious heat at #BullpenBoston June 15 - 18 during BIO International Convention. Click here to request to be added to the #BIO2025 Bullpen invite list: https://lnkd.in/en_s_YMF Bullpen seeks Life Science Dealmakers who live by our mantra and wish to grow authentic connections with like-minded leaders. Bullpen is an invite-only Club gathering Life Science Dealmakers with the shared goal of helping each other. We prepare for and attend premier Life Science events together including JPM Week and BIO International Convention. Our Members represent public and private companies, funds, offices, strategics, bankers, brokers, agencies, accelerators, studios, associations, non-profits, institutions and other critical entities. Connect with an inimitable Club to ignite your life science ventures. Spring Training Miami:?https://lnkd.in/g6aK7jKu Our Mission:?https://lnkd.in/gemP3WGC Become a Member:?https://lnkd.in/gfnyBEpK Upcoming Schedule:?https://lnkd.in/giP5dNkR Bullpen Management:?https://lnkd.in/gV8C4XRK

  • 查看Pluristyx, Inc.的组织主页

    2,953 位关注者

    Check it out! Pluristyx has joined forces with Teknova, a leading reagents manufacturer, to expand access to our proprietary cryopreservation system, PluriFreeze.

  • ?? PluriPost Alert - Exploring Genetic Stability in iPSCs ?? Our team recently delved into the genetic stability of cultured induced pluripotent stem cells (iPSCs) in a new publication. We're excited to expand on their insights and highlight how Pluristyx's approaches and technologies can help. ?? Genetic Abnormalities in iPSCs: Continuous propagation of cells inevitably leads to genetic abnormalities, raising concerns for PSC-derived cell therapies. These changes occur stochastically, but selective pressures in cell culture can favor growth-advantageous alterations, potentially leading to malignant outgrowths in patients. ??? Mitigating Risks: At Pluristyx, we prioritize understanding, minimizing, and mitigating these genetic occurrences. Here are some of our strategies: ? 1. Careful Donor Selection: We select donors based on age, gender, blood type, and collection site to ensure genetic integrity. For example, we prefer skin fibroblasts from less sun-exposed areas and mesenchymal stem cells for their UV protection. 2. Robust Screening: Using NGS-based probing, we screen donor cells for genetic abnormalities to establish confidence in the starting material. 3. Minimizing Cell Stress: Our cell reprogramming and banking protocols minimize cell stress, ensuring a healthy and stable iPSC population. We use small molecules like ROCK inhibitors and nucleoside supplementation to reduce selective pressure and DNA alterations. 4. Genetic Integrity Checkpoints: We implement stage-appropriate checkpoints during cell expansion and after banking to detect genetic abnormalities early. This includes CNV analysis and gene amplification probing. 5. Molecular Safety Switches: Technologies like the FailSafe? mechanism provide an inducible cell suicide switch, activated by Ganciclovir, to remove target cells if DNA alterations are detected. At Pluristyx, Inc., we are committed to delivering safe and effective starting material for cell therapies. Let's continue to innovate and ensure the highest standards for patient safety. Read more: https://lnkd.in/gBmUErjF #CellTherapy #iPSCs #GeneticStability #Pluristyx #Biotech #StemCells?

  • Congratulations to BlueRock Therapeutics and Bayer on receiving Fast Track designation from the FDA for OpCT-001, an investigational iPSC-derived cell therapy for the treatment of primary photoreceptor diseases! ?? At Pluristyx, we believe that iPSCs have tremendous potential as the foundation for next-generation cell therapies and regenerative medicines. This milestone exemplifies the remarkable progress being made in using iPSC-based therapies to treat serious medical conditions and enhance the lives of patients. As we continue to advance off-the-shelf, scalable iPSC solutions, we celebrate the teams at BlueRock and Bayer for their dedication to developing innovative, life-changing treatments, bringing vision and hope back to patients facing these devastating disorders. Read more: https://lnkd.in/eS2NcTXj #CellTherapy #RegenerativeMedicine #iPSCs #StemCells #Biotech #FDAApproval

    • 该图片无替代文字
  • Join us for an informative webinar: ?????????????? ?????????????????????? ???????? ??????????: ???????? ?????????????? ???? ?????????????????? ?????????????????????????????? ?????? ???????????????????? Industry experts Dr. Benjamin Fryer and Dr. Christina Jones, Ph.D. will share their scientific insights on efficient methods for differentiating iPSCs into cardiomyocytes and natural killer cells and tackling concerns over uncontrolled proliferation, genetic mutations, and other safety risks. ?? Date: Mar 20, 2025 ?? Time: 2:00-3:00 PM EDT Don't miss this opportunity to enhance your knowledge and stay ahead in the field of cell therapy development. Register now! ?? Register now: https://lnkd.in/gkdyja5U #CellTherapy #iPSCs #RegenerativeMedicine #Webinar #Pluristyx #CharlesRiver

    • 该图片无替代文字
  • 查看Pluristyx, Inc.的组织主页

    2,953 位关注者

    Pretty darn cool technology towards a "universal stem cell" #stemcells #celltherapy #regenerativemedicine #iPSC

    查看Pluristyx, Inc.的组织主页

    2,953 位关注者

    ?? ??.??. ???????????? ???????????????? ?????? ???????? ??????????????? ?????????????????????? We're excited to announce the issuance of U.S. Patent No. 12,178,835 for our exclusively licensed iACT Stealth? technology! This innovation helps cell therapy products avoid rejection, reducing or eliminating the need for immunosuppression. It is available as a stand-alone product or in combination with FailSafe? technology and our iPSCs. ?? Patents have also been issued in Australia, China, Israel, Japan, Korea, and Great Britain, with more pending globally. ?? Check out our press release: https://lnkd.in/g7meE9UW #CellTherapy #Innovation #Healthcare #Biotech #Pluristyx

    • 该图片无替代文字
  • 查看Pluristyx, Inc.的组织主页

    2,953 位关注者

    We are profoundly saddened by the loss of Dr. Roger Pedersen, a distinguished Stanford professor. For more than four decades, Roger’s pioneering work in early mammalian development and stem cell biology helped shape the foundation of regenerative medicine as we know it today. Roger's contributions to the scientific community have been immense. He was a brilliant scientist, a dedicated mentor, a passionate advocate for stem cell research, and a true pioneer in the field.? His curiosity, kindness, and tireless dedication to advancing science left an enduring impact on the research community and beyond. At Pluristyx, we were incredibly fortunate to benefit from Roger’s insights and expertise as a member of our Scientific Advisory Board. His was a life well lived with a lasting legacy that continues to shape the future of medicine – one that we can all hope to aspire to. ? Our deepest sympathies go out to his family, friends, and colleagues. He will be greatly missed.?

    • 该图片无替代文字
  • 查看Pluristyx, Inc.的组织主页

    2,953 位关注者

    ????????????????????????????? ?????????????????????????? ?????? ???? ?????????? ?????? ?????????? ???? ????????????????????? Today, we honor the incredible women at Pluristyx, Inc. who are making groundbreaking contributions to #CellTherapy and #RegenerativeMedicine. Their dedication, passion, and brilliance inspire us all. From pioneering research to transformative solutions, these women are shaping the future of science and technology. Let's continue to support and empower women (and girls) in STEM, ensuring a brighter, more inclusive future for all. #WomenInScience #STEM #InternationalDayOfWomenAndGirlsInScience #Pluristyx

    • 该图片无替代文字
  • Pluristyx, Inc.转发了

    查看Pluristyx, Inc.的组织主页

    2,953 位关注者

    ?? ??.??. ???????????? ???????????????? ?????? ???????? ??????????????? ?????????????????????? We're excited to announce the issuance of U.S. Patent No. 12,178,835 for our exclusively licensed iACT Stealth? technology! This innovation helps cell therapy products avoid rejection, reducing or eliminating the need for immunosuppression. It is available as a stand-alone product or in combination with FailSafe? technology and our iPSCs. ?? Patents have also been issued in Australia, China, Israel, Japan, Korea, and Great Britain, with more pending globally. ?? Check out our press release: https://lnkd.in/g7meE9UW #CellTherapy #Innovation #Healthcare #Biotech #Pluristyx

    • 该图片无替代文字

相似主页

查看职位

融资